Molecular markers (PECAM-1, ICAM-3, HLA-DR) determine prognosis in primary non-Hodgkin’s gastric lymphoma patients

Figure 1 Positive membrane immunostaining (A) and endothelial staining (B) for PECAM-1 in diffusely growing lymphocytes (magnification 1X400). Gastric glands were identified as negatively stained.

Figure 2 Positive membrane immunostaining for ICAM-3 in diffusely growing lymphocytes (magnification 1X400) (A) and fluctuations of the mean ICAM-3 expression level according to tumor grade (B) and positive intracytoplasm immunostaining for HLA-DR antigen in gastric lymphoma lymphocytes (magnification 1X200) (C) with gastric glands indicated as negatively stained.

Figure 3 Five- year survival according to PECAM-1 (A) and HLA-DR antigen (B) expression (HLA-DR positive patients had expression of HLA-DR antigen in more than 15% of their tumor cells).

Figure 4 Decreased 5 –year survival rate in PECAM-1(+)/ICAM-3(-) (A), and increased 5-year survival rate in HLA-DR(+)/ICAM-3(+) (B) gastric lymphoma patients.

Figure 5 One hundred percent 5-year survival rate in HLA-DR(+)/ICAM-3(+)/PECAM-1(-) gastric lymphoma patients.